Applications For Amendment On 10 October 2012

Matching for 'Applications for Amendment' during October 2012.



Contents

Alerts	3
1 event	3
Terms and Conditions	5
General	5
Disclaimer of warranty and limitation of liability	5
Copyright	5
Arbitration	5

Alerts

1 event

70 results matching for 'Applications for Amendment' during October 2012.

Number	Title	Date
2001261351	Mammalian receptor proteins; related reagents and methods	10 Oct 2012
2001266900	Thrombin receptor antagonists	10 Oct 2012
2001268089	Adenosine A2a receptor antagonists	10 Oct 2012
2001291022	Xanthine phosphodiesterase v inhibitors	10 Oct 2012
2002231049	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents	10 Oct 2012
2002243557	The use of substituted azetidinone compounds for the treatment of sitosterolemia	10 Oct 2012
2002247019	Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications	10 Oct 2012
2002257104	Antifungal composition with enhanced bioavailability	10 Oct 2012
2002258605	Enantioselective synthesis of azetidinone intermediate compounds	10 Oct 2012
2002335770	Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)	10 Oct 2012
2002336609	Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors	10 Oct 2012
2002350081	Ribavirin syrup formulations	10 Oct 2012
2003208888	Uses of mammalian cytokine; related reagents	10 Oct 2012
2003213142	Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same	10 Oct 2012
2003221932	Tricyclic thrombin receptor antagonists	10 Oct 2012
2003241590	Neutralizing human anti-IGFR antibody	10 Oct 2012
2003263071	Pyrazolopyrimidines as cyclin-dependent kinase inhibitors	10 Oct 2012
2003270846	Pyrazolopyridines as cyclin dependent kinase inhibitors	10 Oct 2012
2003295332	Imidazopyridines as cyclin dependent kinase inhibitors	10 Oct 2012
2003298571	Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors	10 Oct 2012
2003301114	Uses of mammalian cytokine; related reagents	10 Oct 2012
2003304527	Uses of adenosine A2a receptor antagonists	10 Oct 2012
2004219625	Uses of IL-23 agonists and antagonists; related reagents	10 Oct 2012
2004242454	Renal cell carcinoma treatment	10 Oct 2012
2004242456	CML therapy	10 Oct 2012
2004257781	Treatment and diagnosis of neoplasms using Thymic Stromal Lymphopoietin	10 Oct 2012
2004268614	Combination therapy for the treatment of ocular neovascular disorders	10 Oct 2012
2004276327	Thrombin receptor antagonists	10 Oct 2012
2004290044	Interleukin-10 antibodies	10 Oct 2012
2004292554	Anti-IGFR1 antibody therapeutic combinations	10 Oct 2012
2004293811	IL-23 and its receptor; related reagents and methods	10 Oct 2012
2005202357	Piperazine derivatives useful as CCR5 antagonists	10 Oct 2012
2005202420	Mammalian cytokines; related reagents and methods	10 Oct 2012
2005206489	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist	10 Oct 2012
2005210504	Crystalline polymorphs of a CXCchemokine receptor ligand	10 Oct 2012
2005212409	Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors	10 Oct 2012
2005215527	Methods of modulating IL-23 activity; related reagents	10 Oct 2012

www.ipmonitor.com.au 3 of 5

Number	Title	Date
2005215528	Use for interleukin-33 (IL33) and the IL33 receptor complex	10 Oct 2012
2005219824	Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus	10 Oct 2012
2005220271	Combination therapy comprising ribavirin and interferon alpha in antiviral treatment haive patients having g chronic hepatitis C infection	10 Oct 2012
2005234666	Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)	10 Oct 2012
2005241020	Use of IL-17 expression to predict skin inflammation; methods of treatment	10 Oct 2012
2005246926	The use of substituted azetidinone compounds for the treatment of sitosterolemia	10 Oct 2012
2005247906	Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors	10 Oct 2012
2005272862	Stable pegylated interferon formulation	10 Oct 2012
2005311930	Substituted piperazines as CB1 antagonists	10 Oct 2012
2005329401	Reducing mercury emissions from the burning of coal	10 Oct 2012
2006203175	Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications	10 Oct 2012
2006217529	Crystalline ACAT inhibitor	10 Oct 2012
2006222684	Human receptor proteins; related reagents and methods	10 Oct 2012
2006252553	Combination of HCV protease inhibitors with a surfactant	10 Oct 2012
2007200876	Neutralizing human anti-IGFR antibody	10 Oct 2012
2007201970	Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications	10 Oct 2012
2007202362	Mammalian receptor proteins; related reagents and methods	10 Oct 2012
2007202938	Methods of modulating CD200 receptors	10 Oct 2012
2007247760	Device for processing foodstuffs	10 Oct 2012
2007285556	Well treatment	10 Oct 2012
2008200842	Tricyclic thrombin receptor antagonists	10 Oct 2012
2008201609	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications	10 Oct 2012
2008203172	OX2 receptor homologs	10 Oct 2012
2008303081	A variable transmission	10 Oct 2012
2009200018	Methods of increasing endogenous erythropoietin (EPO)	10 Oct 2012
2009200460	Stable extended release oral dosage composition	10 Oct 2012
2009238193	Vehicle window wiper assembly	10 Oct 2012
2009251147	Dynamic printer modelling for output checking	10 Oct 2012
2010214749	Uses of adenosine A2a receptor antagonists	10 Oct 2012
2011101327	Hinge having self-centering means	10 Oct 2012
2011200606	Interleukin-10 antibodies	10 Oct 2012
2011201590	Method and system for calculating and reporting slump in delivery vehicles	10 Oct 2012
2011236021	Shoe Insole	10 Oct 2012

www.ipmonitor.com.au 4 of 5

Terms and Conditions

General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information conatined in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at www.IPMonitor.com.au/trademarks/info/terms

www.ipmonitor.com.au 5 of 5